US 12,733,821

Application 17/600,775 · Granted Sep 15, 2026

Implantable cerebral sensing devices and systems and methods related thereto

Estimated expiration

March 18, 2043

16y 121d remaining

Confidence: high
High: no high-severity warning was raised, and any terminal disclaimer was resolved to the patents it references.
Earliest effective filing
Apr 1, 2020
+ 20 years
Apr 1, 2040
PTA +1081d
Mar 18, 2043
No TD
—
Final
Mar 18, 2043

This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.

Calculation details

Base term

Filing date
October 1, 2021
Earliest effective filing
April 1, 2020
Issue date
September 15, 2026
PTA
+1081 days
Base expiry (before PTA)
April 1, 2040

April 1, 2020 + 20 years = April 1, 2040 + 1081 PTA days = March 18, 2043

  • National stage entry of application PCTUS2020026100, filed Apr 1, 2020
  • PRO62/827,999 — Provisional — not used for base term
  • PRO62/827,999 — Provisional — not used for base term

Terminal disclaimers

No TD0 approved, 0 filed

Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated

You have the date. Your AI can have the file.

Application 17/600,775 · US 12,733,821

PatentReply compiles the prosecution history behind US 12,733,821: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.

One new published application a month is free. The first compile takes a few minutes.

Strategy and filing changes require your approval.

How PatentReply handles an Office Action response →

Permanent link

www.patentreply.ai/tools/patent-expiration/US12733821

Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.